MEDIUM confidence: 100% data completeness, but the composite (56) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Avg target $547 (last qtr, 8 analysts) → $0 (last mo, 0) (-100.0%).
Buy-rated share 79% → 82% over ~3 months (+2pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| May 2026 | $4.24 | $4.47 | +5.4% |
| Feb 2026 | $5.11 | $5.03 | -1.6% |
| Nov 2025 | $4.57 | $4.80 | +5.0% |
| Aug 2025 | $4.29 | $4.52 | +5.4% |
| May 2025 | $4.25 | $4.06 | -4.5% |
| Feb 2025 | $4.02 | $3.98 | -1.0% |
| Nov 2024 | $4.14 | $4.38 | +5.8% |
| Aug 2024 | $-11.63 | $-12.83 | -10.3% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7.6B— | $8.9B+17.9% | $9.9B+10.5% | $11.0B+11.7% | $12.1B+9.6% |
| EPS (dil.) | $9.01— | $12.82+42.3% | $13.89+8.3% | $-2.08-115.0% | $15.32n/m |
| Free Cash Flow | $2.4B— | $3.9B+63.0% | $3.3B-16.5% | -$790M-124.1% | $3.2Bn/m |
| Gross Margin | 88.1% | 87.9%-0.2pp | 87.2%-0.7pp | 86.1%-1.1pp | 85.0%-1.1pp |
| Operating Margin | 36.7% | 48.2%+11.5pp | 38.8%-9.4pp | -2.1%-40.9pp | 39.4%+41.5pp |
| Net Margin | 30.9% | 37.2%+6.3pp | 36.7%-0.5pp | -4.9%-41.5pp | 32.7%+37.6pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$67.5M over 180 days (0 open-market buys, 48 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
The QScore of 56 indicates a neutral outlook for Vertex Pharmaceuticals, driven by a strong growth profile, with notable revenue and EPS growth of 9.6% and 843.3%, respectively. However, the stock's value score is dragged down by its premium valuation, with a P/E of 28.9 and P/B of 6.4. The company exhibits strong profitability, with an ROE of 23.9% and operating margin of 39.0%, while its momentum is moderate, with a 12-month return of 10.2% and an RSI of 75.5.